Treatment of renal cell carcinoma: Current status and future directions

被引：685

作者：

Barata, Pedro C. ^{[1
]}

Rini, Brian I. ^{[2
,3
]}

机构：

[1] Cleveland Clin, Taussig Canc Inst, Dept Hematol & Med Oncol, Cleveland, OH 44106 USA

[2] Cleveland Clin, Lerner Coll Med, Med, Cleveland, OH 44106 USA

[3] Cleveland Clin, Taussig Canc Inst, Genitourinary Program, Glickman Urol & Kidney Inst,Dept Hematol & Oncol, Cleveland, OH 44106 USA

来源：

CA-A CANCER JOURNAL FOR CLINICIANS | 2017年 / 67卷 / 06期

关键词：

clinical trials; immunotherapy; programmed death 1 (PD-1); renal cell carcinoma; targeted agents; vascular endothelial growth factor (VEGF); ENDOTHELIAL GROWTH-FACTOR; DOSE RECOMBINANT INTERLEUKIN-2; INTEGRATED STAGING SYSTEM; INITIAL TARGETED THERAPY; PHASE-III TRIAL; RADICAL NEPHRECTOMY; INTERFERON-ALPHA; OPEN-LABEL; DOUBLE-BLIND; HIGH-RISK;

D O I：

10.3322/caac.21411

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Over the past 12 years, medical treatment for renal cell carcinoma (RCC) has transitioned from a nonspecific immune approach (in the cytokine era), to targeted therapy against vascular endothelial growth factor (VEGF), and now to novel immunotherapy agents. Multiple agentsincluding molecules against vascular endothelial growth factor, platelet-derived growth factor, and related receptors; inhibitors of other targets, such as the mammalian target of rapamycin and the MET and AXL tyrosine-protein kinase receptors; and an immune-checkpoint inhibitorhave been approved based on significant activity in patients with advanced RCC. Despite these advances, important questions remain regarding biomarkers of efficacy, patient selection, and the optimal combination and sequencing of agents. The purpose of this review is to summarize present management and future directions in the treatment of metastatic RCC. CA Cancer J Clin 2017;67:507-524. (c) 2017 American Cancer Society.

引用

页码：507 / 524

页数：18

共 167 条

[31]

[Anonymous], STUDY ATEZOLIZUMAB A

[32]

[Anonymous], PHAS 2 STUD ALT SUN

[33] Everolimus versus sunitinib for patients with metastatic non-clear-cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial [J].

Armstrong, Andrew J. ;

Halabi, Susan ;

Eisen, Tim ;

Broderick, Samuel ;

Stadler, Walter M. ;

Jones, Robert J. ;

Garcia, Jorge A. ;

Vaishampayan, Ulka N. ;

Picus, Joel ;

Hawkins, Robert E. ;

Hainsworth, John D. ;

Kollmannsberger, Christian K. ;

Logan, Theodore F. ;

Puzanov, Igor ;

Pickering, Lisa M. ;

Ryan, Christopher W. ;

Protheroe, Andrew ;

Lusk, Christine M. ;

Oberg, Sadie ;

George, Daniel J. .

LANCET ONCOLOGY, 2016, 17 (03) :378-388

[34] Axitinib in combination with pembrolizumab in patients (pts) with advanced renal cell carcinoma (aRCC): Preliminary safety and efficacy results [J].

Atkins, M. B. ;

Plimack, E. R. ;

Puzanov, I. ;

Fishman, M. N. ;

McDermott, D. ;

Cho, D. C. ;

Vaishampayan, U. ;

George, S. ;

Olencki, T. ;

Tarazi, J. ;

Rosbrook, B. ;

Fernandez, K. ;

Keefe, S. ;

Choueiri, T. .

ANNALS OF ONCOLOGY, 2016, 27

[35]

Atkins MB, 2015, J IMMUNOTHER CANCER, V3, P353, DOI DOI 10.1186/2051-1426-3-S2-P353

[36] IL-2 in combination with IFN-α and 5-FU versus tamoxifen in metastatic renal cell carcinoma:: long-term results of a controlled randomized clinical trial [J].

Atzpodien, J ;

Kirchner, H ;

Illiger, HJ ;

Metzner, B ;

Ukena, D ;

Schott, H ;

Funke, PJ ;

Gramatzki, M ;

von Jürgensom, S ;

Wandert, T ;

Patzelt, T ;

Reitz, M .

BRITISH JOURNAL OF CANCER, 2001, 85 (08) :1130-1136

[37] Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma:: A prospectively German cooperative renal randomized trial of the carcinoma chemoimmunotherapy group (DGCIN) [J].

Atzpodien, J ;

Kirchner, H ;

Jonas, U ;

Bergmann, L ;

Schott, H ;

Heynemann, H ;

Fornara, P ;

Loening, SA ;

Roigas, J ;

Müller, SC ;

Bodenstein, H ;

Pomer, S ;

Metzner, B ;

Rebmann, U ;

Oberneder, R ;

Siebels, M ;

Wandert, T ;

Puchberger, T ;

Reitz, M .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (07) :1188-1194

[38] Novel immunotherapies in lymphoid malignancies [J].

Batlevi, Connie Lee ;

Matsuki, Eri ;

Brentjens, Renier J. ;

Younes, Anas .

NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (01) :25-40

[39] Contemporary external validation of the Leibovich model for prediction of progression after radical surgery for clear cell renal cell carcinoma [J].

Beisland, Christian ;

Gudbrandsdottir, Gigja ;

Reisaeter, Lars A. R. ;

Bostad, Leif ;

Wentzel-Larsen, Tore ;

Hjelle, Karin M. .

SCANDINAVIAN JOURNAL OF UROLOGY, 2015, 49 (03) :205-210

[40] Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis [J].

Bracarda, S. ;

Iacovelli, R. ;

Boni, L. ;

Rizzo, M. ;

Derosa, L. ;

Rossi, M. ;

Galli, L. ;

Procopio, G. ;

Sisani, M. ;

Longo, F. ;

Santoni, M. ;

Morelli, F. ;

Di Lorenzo, G. ;

Altavilla, A. ;

Porta, C. ;

Camerini, A. ;

Escudier, B. .

ANNALS OF ONCOLOGY, 2015, 26 (10) :2107-2113

← 1 2 3 4 5 6 7 8 9 10 →